

Bernhard Witzenbichler

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2070469/bernhard-witzenbichler-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

186
papers

11,517
citations

46
h-index

104
g-index

192
ext. papers

13,711
ext. citations

6.8
avg, IF

5.44
L-index

#	Paper	IF	Citations
186	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI: An ADAPT-DES Substudy.. <i>JACC: Cardiovascular Interventions</i> , 2022 ,	5	3
185	Dual Antiplatelet Therapy Discontinuation, Platelet Reactivity, and Adverse Outcomes After Successful Percutaneous Coronary Intervention.. <i>JACC: Cardiovascular Interventions</i> , 2022 , 15, 797-806	5	0
184	Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1968-1986	15.1	0
183	Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2021 , 10, e021418	6	0
182	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e010565	6	1
181	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 444-456	5	3
180	Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 417-427	5	4
179	Stent Expansion Indexes to Predict Clinical Outcomes: An IVUS Substudy From ADAPT-DES. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1639-1650	5	3
178	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021 , 42, 4683-4693	9.5	5
177	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1857-1866	5	2
176	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021 , 42, 4624-4634	9.5	6
175	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e008226	6	9
174	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2403-2413	15.1	34
173	Ticagrelor With or Without Aspirin After Complex PCI. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2414-2424	15.1	58
172	Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 96, 793-807	2.7	5
171	Comparison of Age (. <i>American Journal of Cardiology</i> , 2020 , 125, 685-693	3	1
170	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020 , 41, 3533-3545	9.5	37

169	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 2238-2247	5	11
168	Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized Trial. <i>Annals of Internal Medicine</i> , 2020 , 173, 436-444	8	30
167	Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2020 , 142, 2329-2337	16.7	14
166	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2019 , 381, 1524-1534	59.2	327
165	Relationship Between Stent Diameter, Platelet Reactivity, and Thrombotic Events After Percutaneous Coronary Artery Revascularization. <i>American Journal of Cardiology</i> , 2019 , 124, 1363-1371	3	1
164	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019 , 381, 2032-2042	59.2	395
163	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 983-992	5	6
162	Cardiac Magnetic Resonance Imaging in Patients with Acute Ischemic Stroke and Elevated Troponin: A Troponin Elevation in Acute Ischemic Stroke (TRELAS) Sub-Study. <i>Cerebrovascular Diseases Extra</i> , 2019 , 9, 19-24	2.1	5
161	Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. <i>American Heart Journal</i> , 2019 , 211, 68-76	4.9	2
160	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1704-1711	7	2
159	Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT-DES Study). <i>American Journal of Cardiology</i> , 2019 , 124, 1380-1388	3	3
158	Impact of Smoking on Platelet Reactivity and Clinical Outcomes After Percutaneous Coronary Intervention: Findings From the ADAPT-DES Study. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007982	6	4
157	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e004945	5.8	3
156	Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. <i>Clinical Research in Cardiology</i> , 2019 , 108, 643-650	6.1	12
155	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2019 , 123, 709-716	3	3
154	Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study). <i>American Journal of Cardiology</i> , 2019 , 123, 549-557	3	2
153	Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study. <i>American Heart Journal</i> , 2018 , 197, 142-149	4.9	4
152	Bleeding Severity After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e005542	6	8

151	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e006144	6	15
150	Percutaneous coronary intervention of bifurcation lesions and platelet reactivity. <i>International Journal of Cardiology</i> , 2018 , 250, 92-97	3.2	4
149	Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. <i>International Journal of Cardiology</i> , 2018 , 268, 61-67	3.2	18
148	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , 2018 , 122, 1638-1646	3	12
147	Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents. <i>American Heart Journal</i> , 2018 , 205, 77-86	4.9	2
146	Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 1277-1286	5	7
145	Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e006853	6	9
144	Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e006243	6	22
143	Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 650-658	4.3	4
142	Angiographic predictors of 2-year stent thrombosis in patients receiving drug-eluting stents: Insights from the ADAPT-DES study. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, 26-35	2.7	14
141	Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	17
140	Percutaneous Coronary Intervention of Saphenous Vein Graft. <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	22
139	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. <i>International Journal of Cardiology</i> , 2017 , 243, 132-139	3.2	8
138	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 645-654	5	15
137	Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	5
136	Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage strategy and Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trials). <i>American Journal of Cardiology</i> , 2017 , 119, 1710-1716	3	26
135	Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. <i>International Journal of Cardiology</i> , 2017 , 231, 61-67	3.2	45
134	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	15

133	Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. <i>International Journal of Cardiology</i> , 2017 , 246, 20-25	3.2	11
132	Comparison of plaque morphology between peripheral and coronary artery disease (from the CLARITY and ADAPT-DES IVUS substudies). <i>Coronary Artery Disease</i> , 2017 , 28, 369-375	1.4	11
131	Impact of chronic statin therapy on clinical presentation and underlying lesion morphology in patients undergoing percutaneous intervention: an ADAPT-DES IVUS substudy. <i>Coronary Artery Disease</i> , 2017 , 28, 218-224	1.4	3
130	Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study). <i>American Journal of Cardiology</i> , 2017 , 120, 917-923	3	9
129	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 1607-1617	5	21
128	Does calcium burden impact culprit lesion morphology and clinical results? An ADAPT-DES IVUS substudy. <i>International Journal of Cardiology</i> , 2017 , 248, 97-102	3.2	8
127	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). <i>American Journal of Cardiology</i> , 2017 , 120, 904-910	3	7
126	Relation Between Renal Function and Coronary Plaque Morphology (from the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Virtual Histology-Intravascular Ultrasound Substudy). <i>American Journal of Cardiology</i> , 2017 , 119, 217-224	3	3
125	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, E217-E225	2.7	10
124	Prevalence, Features, and Prognostic Importance of Edge Dissection After Drug-Eluting Stent Implantation: An ADAPT-DES Intravascular Ultrasound Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9, e003553	6	39
123	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1461-9	5	27
122	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. <i>American Journal of Cardiology</i> , 2016 , 118, 1661-1668	3	5
121	Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 42, 186-96	5.1	2
120	Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 87, 391-400	2.7	7
119	Relationship Between Platelet Reactivity and Culprit Lesion Morphology: An Assessment From the ADAPT-DES Intravascular Ultrasound Substudy. <i>JACC: Cardiovascular Imaging</i> , 2016 , 9, 849-854	8.4	10
118	Coronary Angiographic Findings in Acute Ischemic Stroke Patients With Elevated Cardiac Troponin: The Troponin Elevation in Acute Ischemic Stroke (TRELAS) Study. <i>Circulation</i> , 2016 , 133, 1264-71	16.7	73
117	Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). <i>American Journal of Cardiology</i> , 2016 , 117, 192-200	3	12
116	Differences in Underlying Culprit Lesion Morphology Between Men and Women: An IVUS Analysis From the ADAPT-DES Study. <i>JACC: Cardiovascular Imaging</i> , 2016 , 9, 498-9	8.4	13

115	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1349-57	5	36
114	The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1450-7	5	20
113	Predictors and Long-Term Clinical Impact of Acute Stent Malapposition: An Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) Intravascular Ultrasound Substudy. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	20
112	Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. <i>American Journal of Cardiology</i> , 2016 , 117, 1703-13	3	14
111	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2224-2234	15.1	306
110	Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. <i>American Journal of Cardiology</i> , 2016 , 117, 1877-83	3	24
109	Prevalence and Clinical Impact of Tissue Protrusion After Stent Implantation: An ADAPT-DES Intravascular Ultrasound Substudy. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1499-507	5	28
108	Effect of obesity on coronary atherosclerosis and outcomes of percutaneous coronary intervention: grayscale and virtual histology intravascular ultrasound substudy of assessment of dual antiplatelet therapy with drug-eluting stents. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8,	6	15
107	Cerebrovascular events after a primary percutaneous coronary intervention strategy for acute ST-segment-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8,	6	1
106	Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry: Insights From ADAPT-DES. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8,	6	8
105	Usefulness of the Left Anterior Descending Coronary Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). <i>American Journal of Cardiology</i> , 2015 , 116, 1658-65	3	12
104	Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8,	6	34
103	Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1036-45	15.1	239
102	Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002475	6	97
101	Comparison of Stent Expansion Guided by Optical Coherence Tomography Versus Intravascular Ultrasound: The ILUMIEN II Study (Observational Study of Optical Coherence Tomography [OCT] in Patients Undergoing Fractional Flow Reserve [FFR] and Percutaneous Coronary Intervention). <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1704-14	5	106
100	Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: three year results from the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015 , 85, 359-68	2.7	80
99	Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST-segment elevation myocardial infarction: results of the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015 , 85, 335-42	2.7	16
98	Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015 , 85, 371-9	2.7	12

97	Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e001683	6	47
96	Age-related effects of smoking on culprit lesion plaque vulnerability as assessed by grayscale and virtual histology-intravascular ultrasound. <i>Coronary Artery Disease</i> , 2015 , 26, 476-83	1.4	9
95	Morphological changes and clinical impact of unstable plaques within untreated segments of acute myocardial infarction patients during a 3-year follow-up: an analysis from the HORIZONS-AMI trial. <i>Coronary Artery Disease</i> , 2015 , 26, 469-75	1.4	4
94	Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1978-1987	5	22
93	Etiology, Frequency, and Clinical Outcomes of Myocardial Infarction After Successful Drug-Eluting Stent Implantation: Two-Year Follow-Up From the ADAPT-DES Study. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002447	6	9
92	Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction: An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1966-1974	5	41
91	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 27-38	15.1	54
90	Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: lessons from HORIZONS-AMI. <i>American Heart Journal</i> , 2015 , 169, 242-8	4.9	9
89	Comparison of plaque characteristics in narrowings with ST-elevation myocardial infarction (STEMI), non-STEMI/unstable angina pectoris and stable coronary artery disease (from the ADAPT-DES IVUS Substudy). <i>American Journal of Cardiology</i> , 2015 , 115, 860-6	3	35
88	Incidence and potential mechanism of resolved, persistent and newly acquired malapposition three days after implantation of self-expanding or balloon-expandable stents in a STEMI population: insights from optical coherence tomography in the APPOSITION II study. <i>EuroIntervention</i> , 2015 , 11, 885-94	3.1	11
87	D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 37, 155-64	5.1	38
86	Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. <i>European Heart Journal</i> , 2014 , 35, 1533-40	9.5	164
85	Outcomes in diabetic patients undergoing primary percutaneous coronary intervention for acute anterior myocardial infarction: results from the INFUSE-AMI study. <i>Catheterization and Cardiovascular Interventions</i> , 2014 , 83, 704-10	2.7	16
84	Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. <i>Circulation</i> , 2014 , 129, 463-70	16.7	267
83	Incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial. <i>Circulation: Cardiovascular Interventions</i> , 2014 , 7, 543-51	6	49
82	Postprocedural anticoagulation for specific therapeutic indications after revascularization for ST-segment elevation myocardial infarction (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial). <i>American Journal of Cardiology</i> , 2014 , 114, 1333-6	3	3
81	Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction). <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 733-40	5	38
80	Comparison of outcomes in patients with ST-segment elevation myocardial infarction discharged on versus not on statin therapy (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). <i>American Journal of Cardiology</i> , 2014 , 113, 1273-9	3	10

79	Impact of pre-procedural cardiopulmonary instability in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). <i>American Journal of Cardiology</i> , 2014 , 114, 962-7	3	2
78	Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). <i>American Journal of Cardiology</i> , 2014 , 113, 1457-60	3 ²	3 ²
77	Impact of multiple complex plaques on short- and long-term clinical outcomes in patients presenting with ST-segment elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial). <i>American Journal of Cardiology</i> , 2014 , 113, 1621-7	3	9
76	The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014 , 3, 67-77	4.3	49
75	Body mass index and acute and long-term outcomes after acute myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). <i>American Journal of Cardiology</i> , 2014 , 114, 9-16	3	29
74	Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 81, E9-14	2.7	6
73	Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial. <i>American Heart Journal</i> , 2013 , 166, 64-70	4.9	24
72	Plaque shift and distal embolism in patients with acute myocardial infarction: a volumetric intravascular ultrasound analysis from the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 82, 203-9	2.7	7
71	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet, The</i> , 2013 , 382, 1714-22	4.0	40 ⁵
70	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. <i>Lancet, The</i> , 2013 , 382, 614-23	4.0	60 ⁶
69	Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: analysis from the HORIZONS-AMI trial. <i>American Heart Journal</i> , 2013 , 166, 676-83	4.9	20
68	Dynamic nature of nonculprit coronary artery lesion morphology in STEMI: a serial IVUS analysis from the HORIZONS-AMI trial. <i>JACC: Cardiovascular Imaging</i> , 2013 , 6, 86-95	8.4	48
67	Relation between white blood cell count and final infarct size in patients with ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention (from the INFUSE AMI trial). <i>American Journal of Cardiology</i> , 2013 , 112, 1860-6	3	14
66	Relationship between myocardial reperfusion, infarct size, and mortality: the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 718-24	5	34
65	Outcome of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention during on- versus off-hours (a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial substudy). <i>American Journal of Cardiology</i> , 2013 , 111, 946-54	3	23
64	Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 35, 200-8	5.1	5
63	Long-term prognosis of patients presenting with ST-segment elevation myocardial infarction with no significant coronary artery disease (from the HORIZONS-AMI trial). <i>American Journal of Cardiology</i> , 2013 , 111, 643-8	3	52
62	Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI trial. <i>International Journal of Cardiology</i> , 2013 , 167, 2572-9	3.2	51

61	Comparison of outcomes of patients with ST-segment elevation myocardial infarction with versus without previous coronary artery bypass grafting (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). <i>American Journal of Cardiology</i> , 2013 , 111, 1377-86	3	18
60	Frequency, mechanisms, and implications of late peri-stent contrast staining: analysis (from the HORIZONS-AMI Trial). <i>American Journal of Cardiology</i> , 2013 , 111, 1587-92	3	7
59	Impact of bivalirudin and paclitaxel-eluting stents on outcomes in patients undergoing primary percutaneous coronary intervention of the left anterior descending artery. <i>American Journal of Cardiology</i> , 2013 , 112, 753-60	3	11
58	Comparison of Three-year outcomes after primary percutaneous coronary intervention in patients with left ventricular ejection fraction . <i>American Journal of Cardiology</i> , 2013 , 111, 12-20	3	41
57	Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction: one-year results from the INFUSE-AMI trial. <i>Circulation: Cardiovascular Interventions</i> , 2013 , 6, 527-34	6	48
56	Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: The HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 82, 869-77	2.7	11
55	Coronary reperfusion and clinical outcomes after thrombus aspiration during primary percutaneous coronary intervention: findings from the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 82, 594-601	2.7	8
54	Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. <i>EuroIntervention</i> , 2013 , 8, 1134-42	3.1	37
53	Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. <i>EuroIntervention</i> , 2013 , 8, 1307-14	3.1	26
52	Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. <i>EuroIntervention</i> , 2013 , 9, 220-7	3.1	29
51	Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1752-9	15.1	48
50	Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 1209-19	5	27
49	Self-expanding versus balloon-expandable stents in acute myocardial infarction: results from the APPOSITION II study: self-expanding stents in ST-segment elevation myocardial infarction. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 1209-19	5	69
48	Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial). <i>American Journal of Cardiology</i> , 2012 , 110, 940-7	3	8
47	Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 165-79	5.1	10
46	Usefulness of minimum stent cross sectional area as a predictor of angiographic restenosis after primary percutaneous coronary intervention in acute myocardial infarction (from the HORIZONS-AMI Trial IVUS substudy). <i>American Journal of Cardiology</i> , 2012 , 109, 455-60	3	32
45	Long-term follow-up of attenuated plaques in patients with acute myocardial infarction: an intravascular ultrasound substudy of the HORIZONS-AMI trial. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 185-92	6	16
44	B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 813-20	6	33

43	Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 1817-26	27.4	373
42	Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. <i>European Heart Journal</i> , 2012 , 33, 768-75	9.5	157
41	Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 2309-16	15.1	43
40	Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 2317-26	15.1	192
39	Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. <i>JACC: Cardiovascular Interventions</i> , 2011 , 4, 1011-9	5	89
38	Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. <i>American Heart Journal</i> , 2011 , 162, 663-70	4.9	56
37	Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1750-6	15.1	112
36	Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. <i>Lancet, The</i> , 2011 , 377, 2193-204	40	358
35	Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials). <i>American Journal of Cardiology</i> , 2011 , 108, 918-23	3	39
34	Prognostic utility of left ventricular end-diastolic pressure in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2011 , 108, 1068-74	3	35
33	Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial). <i>American Journal of Cardiology</i> , 2011 , 108, 1387-94	3	24
32	Comparison of direct stenting with conventional stent implantation in acute myocardial infarction. <i>American Journal of Cardiology</i> , 2011 , 108, 1697-703	3	33
31	Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. <i>JACC: Cardiovascular Interventions</i> , 2011 , 4, 760-8	5	28
30	Troponin elevation in acute ischemic stroke (TRELAS)--protocol of a prospective observational trial. <i>BMC Neurology</i> , 2011 , 11, 98	3.1	27
29	The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. <i>JACC: Cardiovascular Interventions</i> , 2011 , 4, 495-502	5	87
28	Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. <i>Circulation</i> , 2011 , 123, 1745-56	16.7	193
27	Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 239-47	6	156
26	Paclitaxel-eluting stents compared with bare metal stents in diabetic patients with acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 130-8	6	8

25	Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: analysis from the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction trial. <i>Circulation</i> , 2011 , 123, 2829-37. 7 p following 2837.	16.7	47
24	Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: the EUROSTAR-II randomised clinical trial. <i>EuroIntervention</i> , 2011 , 7, 64-73	3.1	7
23	Six-month clinical and angiographic results of the STENTYS [®] self-apposing stent in bifurcation lesions. <i>EuroIntervention</i> , 2011 , 7, 580-7	3.1	38
22	Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. <i>EuroIntervention</i> , 2011 , 7, 905-16	3.1	76
21	Serial intravascular ultrasound analysis of the impact of myocardial bridge on neointimal proliferation after coronary stenting in patients with acute myocardial infarction. <i>Journal of Interventional Cardiology</i> , 2010 , 23, 114-22	1.8	9
20	Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 107-13	16.7	139
19	When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 107-13	15.1	79
18	Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1597-604	15.1	69
17	Intravascular ultrasound findings of stent fractures in patients with Sirolimus- and Paclitaxel-eluting stents. <i>American Journal of Cardiology</i> , 2010 , 106, 952-7	3	8
16	Impact of transfer for primary percutaneous coronary intervention on survival and clinical outcomes (from the HORIZONS-AMI Trial). <i>American Journal of Cardiology</i> , 2010 , 106, 1218-24	3	11
15	Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial. <i>American Journal of Cardiology</i> , 2010 , 106, 1527-33	3	39
14	Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 796-802	5	18
13	Volumetric intravascular ultrasound analysis of Paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy. <i>Circulation</i> , 2009 , 120, 1875-82	16.7	44
12	Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1438-46	15.1	130
11	Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. <i>New England Journal of Medicine</i> , 2009 , 360, 1946-59	59.2	577
10	Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. <i>Lancet, The</i> , 2009 , 374, 1149-59	40	308
9	First-in-man (FIM) study of the Stentys bifurcation stent--30 days results. <i>EuroIntervention</i> , 2009 , 4, 566-71	3.1	41
8	Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. <i>Circulation</i> , 2008 , 118, 1722-8	16.7	177

7	Bivalirudin during primary PCI in acute myocardial infarction. <i>New England Journal of Medicine</i> , 2008 , 358, 2218-30	59.2	1457
6	Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention. <i>European Journal of Emergency Medicine</i> , 2008 , 15, 324-9	2.3	13
5	Intramuscular gene transfer of fibroblast growth factor-1 using improved pCOR plasmid design stimulates collateral formation in a rabbit ischemic hindlimb model. <i>Journal of Molecular Medicine</i> , 2006 , 84, 491-502	5.5	12
4	Images in cardiovascular medicine. Myocardial infarction caused by occlusion of Cabrol conduit graft. <i>Circulation</i> , 2005 , 112, e79-80	16.7	15
3	Protective role of angiotensin-1 in endotoxic shock. <i>Circulation</i> , 2005 , 111, 97-105	16.7	174
2	Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. <i>American Journal of Pathology</i> , 1998 , 153, 381-94	5.8	285
1	Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. <i>Circulation</i> , 1998 , 97, 381-90	16.7	403